These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 15195929)

  • 1. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ; Gursel I; Gursel M; Klinman DM
    Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
    Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.
    Jahrsdörfer B; Weiner GJ
    Curr Opin Investig Drugs; 2003 Jun; 4(6):686-90. PubMed ID: 12901226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in immunostimulatory CpG oligonucleotides.
    Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
    Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E; Vollmer J
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis.
    Zeuner RA; Verthelyi D; Gursel M; Ishii KJ; Klinman DM
    Arthritis Rheum; 2003 Jun; 48(6):1701-7. PubMed ID: 12794839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
    Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
    Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of cationic lipid complexed with immunostimulatory DNA.
    Rudginsky S; Siders W; Ingram L; Marshall J; Scheule R; Kaplan J
    Mol Ther; 2001 Oct; 4(4):347-55. PubMed ID: 11592838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to enhancing immune responses stimulated by CpG oligodeoxynucleotides.
    Mutwiri G; van Drunen Littel-van den Hurk S; Babiuk LA
    Adv Drug Deliv Rev; 2009 Mar; 61(3):226-32. PubMed ID: 19162103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
    Miles SA; Sandler AD
    Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides.
    Mutwiri GK; Nichani AK; Babiuk S; Babiuk LA
    J Control Release; 2004 May; 97(1):1-17. PubMed ID: 15147800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG motifs to modulate innate and adaptive immune responses.
    Vollmer J
    Int Rev Immunol; 2006; 25(3-4):125-34. PubMed ID: 16818368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
    Li Y; Kandimalla ER; Yu D; Agrawal S
    Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
    Yao QH; Tang YJ; Gao FH; Tang JY
    Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
    Mason KA; Ariga H; Neal R; Valdecanas D; Hunter N; Krieg AM; Whisnant JK; Milas L
    Clin Cancer Res; 2005 Jan; 11(1):361-9. PubMed ID: 15671567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.